U.S. drug maker Merck is building a $1 billion facility in Wilmington, Delaware, aimed at increasing domestic production of ...

Merck estimates the project will create more than 500 full-time roles and about 4,000 construction jobs. CEO of Main Line ...

Merck CEO Robert Davis spoke about the new state-of-the-art biologics center slated to be based in Wilmington, Delaware that could eventually provide thousands of jobs.

New Jersey-based pharmaceutical giant Merck is investing $1 billion in what company executives described as a continued ...

Merck starts construction on a $1B biologics facility in Wilmington, Del., expected to create 500+ jobs and support Keytruda production.

Merck breaks ground on new $1 billion biologics center of excellence in Wilmington, Delaware: Rahway, New Jersey Wednesday, April 30, 2025, 09:00 Hrs [IST] Merck, known as MSD out ...

The Wilmington lab is expected to be functional by 2028. "The Merck Wilmington Biotech site represents our continued commitment to growing our investments in U.S. manufacturing and has the ...

Merck is expanding domestic manufacturing with a $895 million investment in its Kansas factory, one of several major projects ...

The 470,000-square-foot facility will support the launch and commercial production of next-generation biologics and therapies ...

Merck & Co (MSD) has begun construction on a $1bn biologics centre of excellence, Merck Wilmington Biotech, in Delaware, US.

Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, ...

Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA RAHWAY, N.J., April 29, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as ...